ADC Deals Are Up 1900% in 2026 — Here's the Data

Twenty ADC deals closed between February 27 and August 27, 2026 — a 1900% increase over the single deal recorded in the prior six-month window (August 27, 2025 to February 27, 2026). This is not a gradual uptick. This is a market that went from flatline to frenzy in one half-year, driven by Big Pharma's acute need to reload oncology pipelines with clinically differentiated payloads and novel conjugation chemistry.

The Data — ADC Deal Activity, Period over Period

The raw numbers speak for themselves. A single ADC licensing deal in six months is a drought — the kind that makes biotech CFOs nervous and BD teams question their slide decks. Twenty deals in the subsequent period is a stampede. The swing is so severe that it warrants asking whether H2 2025's lull was the anomaly or whether H1 2026's frenzy is the overcorrection. The answer, based on what the deals themselves reveal, is that both conditions share a root cause: the market spent the back half of 2025 digesting Enhertu's expanded approvals and recalibrating what "next-generation ADC" actually means. Once that recalibration finished, the checkbooks opened.

What's Driving the Trend

Three forces converged to produce this ADC licensing 2026 surge. First, pipeline attrition in traditional small-molecule oncology has accelerated. Several late-stage checkpoint combinations failed or posted marginal PFS gains over the past 18 months, making ADCs with novel targets and payloads the most bankable oncology asset class for pharma companies staring at LOE cliffs between 2028 and 2031. GSK's Hansoh deal, Novartis's dual Myricx agreements — these are not speculative bets. They are pipeline-critical acquisitions by companies whose boards have mandated external innovation in oncology.

Second, the technology itself has matured. Site-specific conjugation, bispecific antibody backbones, and topoisomerase I inhibitor payloads beyond DXd are no longer academic curiosities — they are generating clinical data that supports premium valuations. The Deal Benchmarks on Ambrosia show ADC total deal values climbing 40–60% above 2024 medians for comparable-stage assets, reflecting genuine differentiation rather than hype inflation.

Third, capital markets have cooperated. Biotech IPO and follow-on windows reopened in Q1 2026, giving ADC-focused biotechs leverage to negotiate from a position of strength rather than desperation. When a licensor can credibly threaten to fund Phase 2 internally, the upfront payments go up and the milestone structures tilt toward the seller. That dynamic is visible across the current deal cohort.

Notable Deals

The Hansoh-GSK deal is the anchor transaction in this cycle. At $185M upfront against a $1.7B total deal value, the upfront-to-TDV ratio sits around 10.9% — lean by 2024 standards but consistent with deals where the asset is preclinical or early Phase 1 and the TDV is heavily milestone-loaded. GSK is clearly buying optionality across multiple indications, likely including solid tumors where Enhertu's dominance creates competitive pressure to differentiate on target or payload.

Novartis's dual agreements with Myricx Bio are more revealing. Two separate deals with the same licensor on the same day, one valued at $1.1B and the other at $1.5B, signal a platform-level bet rather than a single-asset license. Novartis is buying access to Myricx's conjugation or linker technology for application across multiple programs. The combined $2.6B in potential milestones makes this one of the largest ADC platform commitments of the year. Upfront figures weren't disclosed, but deals of this structure typically carry $30–80M per agreement at the preclinical stage — run those numbers through the Ambrosia calculator and you'll see they track with current benchmarks for platform-access deals.

Biocytogen's two deals with Whitehawk on the same date, one with a $500M TDV and the other undisclosed, suggest a multi-target agreement with asset-specific milestone tranches. Whitehawk is a newer entity — worth watching whether this is a funded vehicle or a shell structure designed to option assets for downstream sublicensing.

What This Means for BD Teams Right Now

If you are a biotech with a differentiated ADC platform — novel payload, novel target, site-specific conjugation, or bispecific backbone — you are operating in a seller's market. Twenty deals in six months means at least 20 pharma BD teams were actively pursuing ADC assets simultaneously, and the competitive tension among buyers is compressing diligence timelines and inflating economics. Multiple credible bidders are the single most powerful variable in a licensing negotiation. Use it.

For sellers: Push for higher upfronts. The 10–11% upfront-to-TDV ratio in the Hansoh-GSK deal is a floor, not a ceiling, if your asset has Phase 1 data or a differentiated mechanism. Opt-in/opt-out structures at Phase 2 data readout are gaining favor because they let licensors retain upside while giving pharma partners a defined decision point. Avoid full buyouts unless the premium is substantial — the market is still appreciating, and a 2026 buyout at 2025 valuations is a mistake.

For buyers: Speed kills hesitation. The deals above all closed within a three-day window in early July, which means the competitive dynamic among pharma BD teams is real and compressed. If you're running a six-month diligence process on an ADC asset in this market, you will lose the deal to someone running a three-month process. Shorten your internal alignment cycles. Pre-negotiate term sheet frameworks with your legal and finance teams so you can move from CDA to term sheet in 8–10 weeks, not 16–20.

On deal structure: Milestone-heavy deals with modest upfronts are the current consensus, but that consensus is starting to crack. As more ADCs generate mid-stage data, expect upfront payments to increase toward 15–20% of TDV for Phase 1/2 assets. Royalty stacking provisions are also becoming a flashpoint — if your ADC uses a licensed payload from a third party, buyers will scrutinize the all-in royalty burden aggressively. Model your royalty stack before you enter negotiations, not during them. The Deal Benchmarks database captures royalty ranges across 200+ ADC deals — use it to anchor your position.

Benchmark your deal against current market rates. Whether you're structuring an upfront, setting milestone triggers, or negotiating royalty tiers, the Ambrosia calculator gives you real-time comps across modality, stage, and therapeutic area. Stop negotiating blind.